Trending...
- Governor Newsom honors fallen California Highway Patrol Officer Miguel Cano - 102
- Governor Newsom marks historic expansion of California's Film and Television Tax Credit Program, announces 16 new projects to film in the Golden State
- California: Governor Newsom announces appointments 7.2.25
CASTRES, France - Californer -- A research team specialized in the study of nervous system disorders has found that NLX-112, a serotonin 5-HT1A receptor agonist developed by Neurolixis, reversed motor deficits in a transgenic model of Spinocerebellar ataxia3 (SCA3), a rare genetic orphan disease. The team led by Prof. Patricia Maciel, at the University of Minho, Portugal, reported online in the journal, Neurobiology of Disease, that NLX-112 restored motor function in nematode worms that express the same gene mutation as that seen in SCA3 patients.
Prof. Maciel commented: "SCA3, also known as Machado-Joseph disease, is an inherited condition. Symptoms including clumsiness, loss of strength, and tremor in the arms and legs that worsen over time, eventually leading to very severe disability. Our new data suggest that NLX-112 may improve the condition of patients suffering from this debilitating disorder."
Neurolixis is now collaborating with Prof. Maciel's team to test NLX-112 in transgenic SCA3 mice. The project, supported by the US Dept. of Defense, will determine whether extended NLX-112 administration attenuates SCA3 symptoms and slows down their development.
More on The Californer
Adrian Newman-Tancredi, CEO of Neurolixis commented: "SCA3 is incurable and there is no approved treatment. If the results seen in the transgenic nematode worm model are translated to transgenic SCA3 mice, Neurolixis will seek to develop NLX-112 in clinical trials for SCA3 patients. NLX-112 has previously been tested in over 500 patients for other indications so we know it is safe and well tolerated."
NLX-112 is currently undergoing a clinical Phase 2A study for treatment of L-DOPA-induced dyskinesia in Parkinson's disease patients and the new SCA3 data suggests that it may also have utility for treatment of additional movement disorders.
Full publication – Open Access
Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease.
Pereira-Sousa et al., Neurobiology of Disease, 28 Jan 2021 (Online ahead of print)
doi: 10.1016/j.nbd.2021.105278, PMID: 33516872
About Neurolixis
Neurolixis is a privately held biotechnology company developing therapies for central nervous system disorders. It has two lead compounds, NLX‑112 (Phase 2) which targets treatment of motor disorders, and NLX-101 (Phase 1), a potential rapid-acting anti-depressant, with utility for treating neuro-developmental disorders including Rett syndrome. In addition, Neurolixis conducts a drug discovery program targeting chronic pain (non-opioid mechanism) and depression.
More on The Californer
About the University of Minho
The mission of University of Minho, founded in 1973, is to create, spread and convert knowledge into value-generating applications. The Life and Health Sciences Research Institute (ICVS) is the Biomedicine R&D Unit of the School of Medicine cluster of the University. The cluster includes 2CA-Braga, a clinical research site that currently runs 1/3 of all clinical trials in Portugal; P5, that with the ICVS conceives and develops new digital medicine products and provides medical services with a digital interface; and B.ACIS, a knowledge transfer interface fostering developments in biomedical research resulting in marketed products that bring clinical benefits to patients.
Prof. Maciel commented: "SCA3, also known as Machado-Joseph disease, is an inherited condition. Symptoms including clumsiness, loss of strength, and tremor in the arms and legs that worsen over time, eventually leading to very severe disability. Our new data suggest that NLX-112 may improve the condition of patients suffering from this debilitating disorder."
Neurolixis is now collaborating with Prof. Maciel's team to test NLX-112 in transgenic SCA3 mice. The project, supported by the US Dept. of Defense, will determine whether extended NLX-112 administration attenuates SCA3 symptoms and slows down their development.
More on The Californer
- Heritage at South Brunswick Offers Immediate Townhome Appointments and Special Mortgage Incentive Fast-Moving Sales
- Sam Sammane wins Literary Titan Award for Republic of Mars, a haunting sci-fi debut on memory
- Fair Trade LA, The Tote Project, and Fair Trade USA™ Distribute 100 "Fair Care Packages" to Families Affected by Los Angeles Fires
- For Third Consecutive Year, ELEVATE Recognized as Star Performer & Major Contender by Everest Group
- NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
Adrian Newman-Tancredi, CEO of Neurolixis commented: "SCA3 is incurable and there is no approved treatment. If the results seen in the transgenic nematode worm model are translated to transgenic SCA3 mice, Neurolixis will seek to develop NLX-112 in clinical trials for SCA3 patients. NLX-112 has previously been tested in over 500 patients for other indications so we know it is safe and well tolerated."
NLX-112 is currently undergoing a clinical Phase 2A study for treatment of L-DOPA-induced dyskinesia in Parkinson's disease patients and the new SCA3 data suggests that it may also have utility for treatment of additional movement disorders.
Full publication – Open Access
Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease.
Pereira-Sousa et al., Neurobiology of Disease, 28 Jan 2021 (Online ahead of print)
doi: 10.1016/j.nbd.2021.105278, PMID: 33516872
About Neurolixis
Neurolixis is a privately held biotechnology company developing therapies for central nervous system disorders. It has two lead compounds, NLX‑112 (Phase 2) which targets treatment of motor disorders, and NLX-101 (Phase 1), a potential rapid-acting anti-depressant, with utility for treating neuro-developmental disorders including Rett syndrome. In addition, Neurolixis conducts a drug discovery program targeting chronic pain (non-opioid mechanism) and depression.
More on The Californer
- Shoot 'Em Up Classic Undeadline Coming to America & Europe for the First Time in New Collector's Set
- Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
- FANATICS AND COMPLEX PRESENT <BLACKPINK IN YOUR AREA> LEAGUE COLLECTION TO CELEBRATE THEIR COMEBACK
- Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
- Project Management Institute San Francisco and TalentCheetah Inc. Announce New Strategic Partnership
About the University of Minho
The mission of University of Minho, founded in 1973, is to create, spread and convert knowledge into value-generating applications. The Life and Health Sciences Research Institute (ICVS) is the Biomedicine R&D Unit of the School of Medicine cluster of the University. The cluster includes 2CA-Braga, a clinical research site that currently runs 1/3 of all clinical trials in Portugal; P5, that with the ICVS conceives and develops new digital medicine products and provides medical services with a digital interface; and B.ACIS, a knowledge transfer interface fostering developments in biomedical research resulting in marketed products that bring clinical benefits to patients.
Source: NEUROLIXIS
0 Comments
Latest on The Californer
- Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
- Amid Trump's assault on public lands, California conserves over one million acres of land and coastal waters in just one year
- California: Governor Newsom announces appointments 7.7.25
- City of Long Beach to Upgrade Its Internet Infrastructure to Enhance City Network Reliability and Performance
- Groflex Named One of the Top 100 Manufacturing Startups in San Francisco by F6S
- BofA Directs Additional $1 Million to Los Angeles Nonprofits for Evolving Fire Recovery Needs
- Introducing LK Blue: The Cool-Girl Denim Brand That's Redefining LA Style Launches E-Commerce
- THINKWARE Announces Prime Day Deals on Best-Selling Dash Cams
- Zeta Sky Strengthens Cybersecurity Support for Ontario Businesses Facing Rising Identity & Complian
- Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest
- Boleros de Noche presents "Marisoul y Los Hermanos Carlos" & "Bolero Soul" at The Ford
- Krispy Kreme, Inc. (DNUT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- The 17th Annual Hola Mexico Film Festival presented by Toyota, September 12-20, during Hispanic Heritage Month, Official Poster Reveal
- NR7 Miner launches zero-cost USDT cloud mining service: daily stable income + referral rewards for double profit
- "The Grateful Dead — 60 Years in San Francisco" - Pantheon Media Launches New Podcast Series and Interactive "Hit Replay" App
- Deaths Spur Closures, but Troubled Teen Camps Must Be Banned, CCHR Warns
- Kiavi Expands Leadership Team to Further Bolster Construction Lending Growth
- Palmer Lake Wine Festival To Build Bridges in Small Mountain Community, Highlight Local Businesses
- Swim Up Hill Appoints Ambassador Lawson, Rep. Towns, and Banker Henderson to Board of Directors
- Paralympic Medalist Jamal Hill Launches Official Road to LA28 Campaign and $3M Corporate Fundraising Initiative